LENZ Therapeutics (LENZ) Operating Income (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Operating Income of -$44.1 million for Q1 2026, down 160.68% year-over-year from $72.7 million in Q1 2025, and down 14.75% quarter-over-quarter from -$38.5 million in Q4 2025.
LENZ Therapeutics (LENZ) Operating Income (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Operating Income for 7 consecutive years, with -$44.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 160.68% year-over-year to -$44.1 million; the TTM figure through Mar 2026 stood at -$118.3 million (down 99.05% YoY), while the FY2025 annual figure was -$91.1 million, down 55.5% from the prior year.
- Operating Income declined to -$44.1 million in Q1 2026 per LENZ's latest filing, from -$38.5 million in the prior quarter.
- Across five years, Operating Income topped out at -$12.6 million in Q1 2023 and bottomed at -$44.1 million in Q1 2026.
- Historically, Operating Income has averaged -$21.9 million across 5 years, with a median of -$18.9 million in 2025.
- Annual changes were most pronounced in 2022 — Operating Income plunged 177.09% — and 2023, when it surged 51.4%.
- LENZ Therapeutics' Operating Income stood at -$26.8 million in 2022, then advanced by 6.59% to -$25.0 million in 2023, then soared by 39.07% to -$15.2 million in 2024, then tumbled by 152.63% to -$38.5 million in 2025, then decreased by 14.75% to -$44.1 million in 2026.
- Business Quant data shows LENZ's Operating Income at -$44.1 million in Q1 2026, -$38.5 million in Q4 2025, and -$18.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | LENZ Therapeutics | 146.20 Mn | 146.20 Mn | 5.21 Mn | -34.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.17 Mn |
| Mar 31, 2026 | -44.14 Mn |
| Dec 31, 2025 | -38.46 Mn |
| Sep 30, 2025 | -18.89 Mn |
| Jun 30, 2025 | -16.86 Mn |
| Mar 31, 2025 | -16.93 Mn |
| Dec 31, 2024 | -15.23 Mn |
| Sep 30, 2024 | -12.95 Mn |
| Jun 30, 2024 | -14.35 Mn |
| Mar 31, 2024 | -16.09 Mn |
| Dec 31, 2023 | -24.99 Mn |
| Sep 30, 2023 | -19.87 Mn |
| Jun 30, 2023 | -14.96 Mn |
| Mar 31, 2023 | -12.62 Mn |
| Dec 31, 2022 | -26.75 Mn |
| Sep 30, 2022 | -26.15 Mn |
| Jun 30, 2022 | -26.78 Mn |
| Mar 31, 2022 | -25.96 Mn |
| Dec 31, 2021 | -18.94 Mn |
| Sep 30, 2021 | -14.60 Mn |